Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × lenvatinib × Endocrine × Clear all

Phase

Status

Completed 4 Recruiting 3 Active not recruiting 3 Terminated 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 53 Gynecologic 3 Thoracic 2 Head & Neck 2 Genitourinary 2 Other solid neoplasm 1 Endocrine 1 Breast 1

Conditions

Thyroid Cancer Metastatic 1

Interventions

lutetium Lu 177 dotatate 6 Everolimus 6 Temozolomide 5 lanreotide 4 anlotinib 4 Dexmedetomidine 4 surufatinib 3 Thyrotropin Alfa 3 Saline Solution 3 Injections 3 Cisplatin 3 Blood Specimen Collection 3 sintilimab 2 penpulimab 2 cabozantinib 2 Surgical Procedures, Operative 2 Sorafenib 2 Sodium Chloride 2 Rosiglitazone 2 Radiotherapy 2 Paclitaxel 2 Nivolumab 2 Lymph Node Excision 2 Liquid Biopsy 2 Fluorodeoxyglucose F18 2 Biopsy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 (177)Lu-DOTA-EB-TATE 2 trametinib 1 toripalimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03732495 2022-03-29

LENVOS

Centre Leon Berard

Phase 2 Unknown

EndocrineHead & Neck

Thyroid Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡